Should adjuvant treatments be escalated in node-positive HR+/HER2- patients achieving pCR and omitting axillary dissection?

IF 5.5 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology Pub Date : 2025-04-29 DOI:10.1016/j.critrevonc.2025.104732

Maria Vita Sanò, Lorenza Marino, Giuseppina Rosaria Rita Ricciardi

引用次数: 0

查看原文本刊更多论文

淋巴结阳性的HR+/HER2-患者实现pCR并省略腋窝清扫，是否应该增加辅助治疗？

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Critical reviews in oncology/hematology 医学-血液学

CiteScore

11.00

自引率

3.20%

发文量

213

审稿时长

55 days

期刊介绍： Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.